期刊
THROMBOSIS RESEARCH
卷 130, 期 -, 页码 S12-S15出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2012.08.262
关键词
cardiovascular disease; biomarker; myocardial infarction; risk factor; atherosclerosis
资金
- Spanish Ministry of Science and Innovation [SAF 2010-16549]
- Institute Carlos III [CIBEROBN-CB06/03, TERCEL -RD06/0010/0017]
- Foundation Jesus Serra Fellowship
- Danone Institute Fellowship
- MICINN-Ramon y Cajal Investigator Contract [RYC-2007-01466]
Cardiovascular diseases (CVD) remain a leading cause of death worldwide. In the past years new biomarkers have drawn the clinician's attention for their use in primary prevention and in the identification of individuals at cardiovascular risk. Biomarkers also provide information on the progression and possible recurrence of cardiovascular events, and include inflammatorymarkers (C-reactive protein and interleukin-18), endothelial dysfunction markers (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1), neurohormonal markers (brain natriuretic peptide and copeptine), ischemia biomarkers (apolipoprotein J) and necrosismarkers (troponins). Although biomarkers provide utility for predicting cardiovascular risk, the identification and characterization of new biomarkers to achieve increasing diagnosis and prognostic efficiency in CVD prevention is of high clinical interest. In this review we will discuss on recently discovered biomarkers and their clinical applications. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据